1809885-32-2 Usage
Description
1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea is a synthetic urea derivative characterized by a complex molecular structure. It features a fluorine-substituted phenyl ring and a piperidin-4-yl moiety connected to a urea functional group. 1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea holds potential pharmaceutical applications due to its structural resemblance to other biologically active drugs. The trifluoromethoxy group may improve the compound's lipophilicity and metabolic stability, while the piperidin-4-yl urea substructure could enhance its binding affinity to biological targets.
Uses
Used in Pharmaceutical Industry:
1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea is used as a potential pharmaceutical agent for its structural similarity to drugs with known biological activity. 1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea's trifluoromethoxy group may contribute to its lipophilicity and metabolic stability, which are desirable properties for drug development. Additionally, the piperidin-4-yl urea substructure could be instrumental in binding to biological targets, making it a candidate for further research and experimentation to determine its exact properties and potential therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1809885-32-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,9,8,8 and 5 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1809885-32:
(9*1)+(8*8)+(7*0)+(6*9)+(5*8)+(4*8)+(3*5)+(2*3)+(1*2)=222
222 % 10 = 2
So 1809885-32-2 is a valid CAS Registry Number.
1809885-32-2Relevant articles and documents
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative
Hammock, Bruce D.,McReynolds, Cindy B.,Wagner, Karen,Buckpitt, Alan,Cortes-Puch, Irene,Croston, Glenn,Lee, Kin Sing Stephen,Yang, Jun,Schmidt, William K.,Hwang, Sung Hee
, p. 1856 - 1872 (2021/03/01)
This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 branch of the arachidonate cascade to stabilize epoxides of polyunsaturated fatty acids (EpFA), which are natural mediators that reduce pain, resolve inflammation, and maintain normal blood pressure. EC5026 is a slow-tight binding transition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations. The sEH rapidly degrades EpFA; thus, inhibiting sEH increases EpFA in vivo and confers beneficial effects. This mechanism addresses disease states by shifting endoplasmic reticulum stress from promoting cellular senescence and inflammation toward cell survival and homeostasis. We describe the synthesis and optimization of EC5026 and its development through human Phase 1a trials with no drug-related adverse events. Additionally, we outline fundamental work leading to discovery of the analgesic and inflammation-resolving CYP450 branch of the arachidonate cascade.
POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS
-
Paragraph 0190; 0191; 0204; 0205; 0206; 0207; 0397-0400, (2015/12/08)
The invention discloses a new series of inhibitors of soluble epoxide hydrolase (sEH) with improved physical properties that enhance their druglikeness to treat sEH associated diseases such as chronic diabetic neuropathic pain.
